| |
|
|
|
|
|
 |
| |
|
°æ³²¼Òµ¶¿ë¿¡Åº¿Ã [Ethanol]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A12050281]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2003.07.01)(ÇöÀç¾à°¡)
\0 ¿ø/1ml(2001.06.23)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
[¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
|
| ºü¸¥Á¶È¸ |
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
- ¼Õ ¹× ÇǺÎÀÇ ¼Òµ¶
- ¼ö¼úºÎÀ§ ÇǺÎÀÇ ¼Òµ¶
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼Òµ¶ºÎÀ§¿¡ ¹Ù¸¥´Ù.
|
| ±Ý±â |
±¸°³», Á¡¸· ¹× ¼Õ»óµÈ ÇǺÎ(ÀÚ±ØÀÛ¿ëÀÌ ÀÖ´Ù)
|
| ÀÌ»ó¹ÝÀÀ |
1) ¹ßÁø µî °ú¹ÎÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì »ç¿ëÀ» ÁßÁöÇÑ´Ù.
2) ÇǺΠ: ÀÚ±ØÁõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì »ç¿ëÀ» ÁßÁöÇÑ´Ù.
|
| Àû¿ë»óÀÇ ÁÖÀÇ |
1) ´«¿¡ µé¾î°¡Áö ¾Êµµ·Ï ÁÖÀÇÇÏ¸ç ¸¸¾à µé¾î°£ °æ¿ì¿¡´Â ¹°·Î ±ú²ýÀÌ ¾Ä¾î³½´Ù.
2) ±¤¹üÀ§ÇÏ°Ô ¶Ç´Â Àå±â°£ »ç¿ëÇÏ´Â °æ¿ì Áõ±â¸¦ ÈíÀÔÇÏÁö ¾Êµµ·Ï ÁÖÀÇÇÑ´Ù(¿¡Åº¿Ã Áõ±â¸¦ ´ë·® ¶Ç´Â ¹Ýº¹ÇÏ¿© ¸¶½Ã´Â °æ¿ì Á¡¸·¿¡ÀÇ ÀÚ±Ø, µÎÅë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
3) µ¿ÀÏ ºÎÀ§¿¡ ¹Ýº¹ »ç¿ëÇÏ´Â °æ¿ì¿¡´Â Å»Áö(÷ò·) µîÀ¸·Î ÇǺΰ¡ °ÅÄ¥¾î Áú ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
4) ÀÎȼº, Æø¹ß¼ºÀÌ ÀÖÀ¸¹Ç·Î ȱâ(Àü±â¸Þ½º »ç¿ëÀ» Æ÷ÇÔ)¿¡ ÁÖÀÇÇÑ´Ù.
5) ÇÕ¼º°í¹«Á¦Ç°, ÇÕ¼º¼öÁöÁ¦Ç°, ±¤Çбⱸ, À¯¸®±â±¸, µµÀå(Óóíû)ÇÑ Ä«Å×ÅÍ µî¿¡ »ç¿ëÀº ÇÇÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏ´Ù. |
| º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ |
¹ÐÆó, Â÷±¤¿ë±â¿¡ ³Ö¾î ȱ⸦ ÇÇÇÏ¿© º¸Á¸ÇÑ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Dµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Ethanol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Ethanol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes.
|
| Pharmacology |
Ethanol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations.
|
| Metabolism |
Ethanol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2E1 (CYP2E1)
|
| Half-life |
Ethanol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Ethanol¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly absorbed.
|
| Pharmacokinetics |
EthanolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ¾à 20%´Â À§¿¡¼, 80%´Â ¼ÒÀå¿¡¼ Èí¼öµÈ´Ù. Áõ±â »óÅ·δ Æó·Îµµ Èí¼öµÉ ¼ö ÀÖ´Ù.
- ºÐÆ÷ :
- ŹÝÀ» ½Å¼ÓÇϰÔ, Àß Åë°úÇϸç, À¯ÁóÀ¸·Îµµ ½Å¼ÓÇÏ°Ô ºÐºñµÈ´Ù.
- ü³» ¸ðµç Á¶Á÷°ú ü¾×¿¡ °ñ°í·ç ±ÕµîÇÏ°Ô ºÐÆ÷ÇÑ´Ù.
- ºÐÆ÷¿ëÀû : 0.53 L/kg (¸¸¼º ¼·Ãë½Ã ³²¼º¿¡¼´Â Áõ°¡ÇÔ)
- ´ë»ç :
- 90-98%´Â °£¿¡¼ alcohol dehydrogenase, aldehyde dehydrogenase¿¡ ÀÇÇØ acetaldehyde, acetyl-CoA·Î Â÷·Ê´ë·Î ´ë»çµÈ ÈÄ citric acid cycleÀ» ÅëÇØ »êȵȴÙ. ƯÈ÷ ÀÌ °æ·ÎÀÇ ´ë»ç°úÁ¤Àº 0Â÷ ¹ÝÀÀ¼Óµµ¸¦ µû¸¥´Ù.
- ÀϺδ °£ÀÇ sER (smooth endoplasmic reticulum)ÀÇ cytochrome P-450 È¿¼Ò°è¿¡ ÀÇÇØ »êȵȴÙ.
- ¹Ý°¨±â : ¿ë·®ÀÇÁ¸Àû
- ¼Ò½Ç : ÁÖ·Î ½Å¹è¼³ (2-10%´Â ¹Ìº¯Èü·Î ½Å¹è¼³)µÇ¸ç, ÀϺδ Æó¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
|
| Biotransformation |
Ethanol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1.
|
| Toxicity |
Ethanol¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, rat LD50: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage.
|
| Drug Interactions |
Ethanol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Ethanol¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
SUBSTRATES
CYP 2E1
acetaminophen
chlorzoxazone
**ethanol**
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
**ethanol**
isoniazid
|
| Drug Target |
[Drug Target]
|
| Description |
Ethanol¿¡ ´ëÇÑ Description Á¤º¸ A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [PubChem]
|
| Drug Category |
Ethanol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, LocalCentral Nervous System DepressantsDisinfectantsSolvents
|
| Smiles String Canonical |
Ethanol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCO
|
| Smiles String Isomeric |
Ethanol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CCO
|
| InChI Identifier |
Ethanol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ Not Available
|
| Chemical IUPAC Name |
Ethanol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ ethanol
|
| Drug-Induced Toxicity Related Proteins |
ETHANOL ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Proenkephalin Drug:ethanol Toxicity:ethanol narcosis. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 1 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Phosphatidylinositol-4-phosphate 3-kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Insulin receptor substrate 2 Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase(Erk2) Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase Drug:Ethanol Toxicity:impair liver regeneration, inhibit DNA synthesis, and mute cellular responses to growth factor stimulation. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-07-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|